Share: Facebook Twitter LinkedIn
Activity Provided By:


Tumor-induced Osteomalacia (TIO): Diagnosis and Management

Access Activity

Overview / Abstract:

Tumor-induced osteomalacia (TIO) is a rare paraneoplastic condition commonly characterized by bone pain, muscle weakness and fractures. These tumors secrete excess fibroblast growth factor 23 (FGF23) which inhibits the sodium phosphate renal co-transporters and suppresses 1α hydroxylase activity, thereby decreasing renal reabsorption and increased urinary phosphate excretion. As a result, unexplainable hypophosphatemia with a variety of musculoskeletal abnormalities are the most common symptoms. Unfortunately, the symptoms are relatively non-specific and phosphate levels are not routinely included in many comprehensive metabolic panels and/or hypophosphatemia is often overlooked. As a result, patients are often misdiagnosed with a variety of skeletal, rheumatologic, or neuro/neuro-psychiatric conditions.

Since the hallmarks of the disease are both pain that fails to respond to standard treatment plus hypophosphatemia, educating clinicians about the pathophysiology of TIO and its signs and symptoms can dramatically reduce the time to diagnose and establish a treatment program that can dramatically improve the patient’s quality of life.

To that end, this CME program is designed to educate clinicians who are likely to see these patients about the pathophysiology and early signs/symptoms of TIO so they are better prepared to recognize this rare but very treatable condition.


Sep 30, 2021


Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME


Webinar / Webcast / Video

Credits / Hours




Presenters / Authors / Faculty

Peter Tebben, MD
Consultant, Division of Pediatric Endocrinology and Metabolism
Department of Pediatric and Adolescent Medicine
Assistant Professor of Medicine
Mayo Clinic
Rochester, MN

Activity Specialities / Related Topics

Pathology, Oncology / Cancer / Radiation Therapy, Neurology, Immunology / Immunosuppression, Genetics

Sponsors / Supporters / Grant Providers

Ultragenyx Pharmaceutical Inc.

Keywords / Search Terms

CheckRare Peter Tebben MD, Pediatric Endocrinology and Metabolism, Mayo Clinic, Tumor-induced osteomalacia (TIO), rare paraneoplastic condition, hypophosphatemia, Ultragenyx, oncology, oncologist, cancer, cancer care, tumor, Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map